carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'lcsm,(-blcsm)', 'atezo', 'tiragolumab', 'sclc']
negative pfs &amp; os benefit results are shared from skyscraper-02 study of tiragolumab (tigit) + chemo + atezo vs chemo+ atezo in the management of patients w/ es-sclc. #lcsm #asco22 
Chief Heme/Onc Education Fellow @MDAndersonNews | Alum of @dukeu @muschealth @vumchealth | Interest in #meded ??#cancer #lcsm | Tweets my own ? medical advice